Artificial Intelligence for the Classification of Pigmented Skin Lesions in Populations with Skin of Color: A Systematic Review.


Journal

Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244

Informations de publication

Date de publication:
2023
Historique:
received: 20 07 2022
accepted: 06 03 2023
medline: 7 8 2023
pubmed: 22 3 2023
entrez: 21 3 2023
Statut: ppublish

Résumé

While skin cancers are less prevalent in people with skin of color, they are more often diagnosed at later stages and have a poorer prognosis. The use of artificial intelligence (AI) models can potentially improve early detection of skin cancers; however, the lack of skin color diversity in training datasets may only widen the pre-existing racial discrepancies in dermatology. The aim of this study was to systematically review the technique, quality, accuracy, and implications of studies using AI models trained or tested in populations with skin of color for classification of pigmented skin lesions. PubMed was used to identify any studies describing AI models for classification of pigmented skin lesions. Only studies that used training datasets with at least 10% of images from people with skin of color were eligible. Outcomes on study population, design of AI model, accuracy, and quality of the studies were reviewed. Twenty-two eligible articles were identified. The majority of studies were trained on datasets obtained from Chinese (7/22), Korean (5/22), and Japanese populations (3/22). Seven studies used diverse datasets containing Fitzpatrick skin type I-III in combination with at least 10% from black Americans, Native Americans, Pacific Islanders, or Fitzpatrick IV-VI. AI models producing binary outcomes (e.g., benign vs. malignant) reported an accuracy ranging from 70% to 99.7%. Accuracy of AI models reporting multiclass outcomes (e.g., specific lesion diagnosis) was lower, ranging from 43% to 93%. Reader studies, where dermatologists' classification is compared with AI model outcomes, reported similar accuracy in one study, higher AI accuracy in three studies, and higher clinician accuracy in two studies. A quality review revealed that dataset description and variety, benchmarking, public evaluation, and healthcare application were frequently not addressed. While this review provides promising evidence of accurate AI models in populations with skin of color, the majority of the studies reviewed were obtained from East Asian populations and therefore provide insufficient evidence to comment on the overall accuracy of AI models for darker skin types. Large discrepancies remain in the number of AI models developed in populations with skin of color (particularly Fitzpatrick type IV-VI) compared with those of largely European ancestry. A lack of publicly available datasets from diverse populations is likely a contributing factor, as is the inadequate reporting of patient-level metadata relating to skin color in training datasets.

Sections du résumé

BACKGROUND BACKGROUND
While skin cancers are less prevalent in people with skin of color, they are more often diagnosed at later stages and have a poorer prognosis. The use of artificial intelligence (AI) models can potentially improve early detection of skin cancers; however, the lack of skin color diversity in training datasets may only widen the pre-existing racial discrepancies in dermatology.
OBJECTIVE OBJECTIVE
The aim of this study was to systematically review the technique, quality, accuracy, and implications of studies using AI models trained or tested in populations with skin of color for classification of pigmented skin lesions.
METHODS METHODS
PubMed was used to identify any studies describing AI models for classification of pigmented skin lesions. Only studies that used training datasets with at least 10% of images from people with skin of color were eligible. Outcomes on study population, design of AI model, accuracy, and quality of the studies were reviewed.
RESULTS RESULTS
Twenty-two eligible articles were identified. The majority of studies were trained on datasets obtained from Chinese (7/22), Korean (5/22), and Japanese populations (3/22). Seven studies used diverse datasets containing Fitzpatrick skin type I-III in combination with at least 10% from black Americans, Native Americans, Pacific Islanders, or Fitzpatrick IV-VI. AI models producing binary outcomes (e.g., benign vs. malignant) reported an accuracy ranging from 70% to 99.7%. Accuracy of AI models reporting multiclass outcomes (e.g., specific lesion diagnosis) was lower, ranging from 43% to 93%. Reader studies, where dermatologists' classification is compared with AI model outcomes, reported similar accuracy in one study, higher AI accuracy in three studies, and higher clinician accuracy in two studies. A quality review revealed that dataset description and variety, benchmarking, public evaluation, and healthcare application were frequently not addressed.
CONCLUSIONS CONCLUSIONS
While this review provides promising evidence of accurate AI models in populations with skin of color, the majority of the studies reviewed were obtained from East Asian populations and therefore provide insufficient evidence to comment on the overall accuracy of AI models for darker skin types. Large discrepancies remain in the number of AI models developed in populations with skin of color (particularly Fitzpatrick type IV-VI) compared with those of largely European ancestry. A lack of publicly available datasets from diverse populations is likely a contributing factor, as is the inadequate reporting of patient-level metadata relating to skin color in training datasets.

Identifiants

pubmed: 36944317
pii: 000530225
doi: 10.1159/000530225
pmc: PMC10407827
doi:

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

499-513

Informations de copyright

© 2023 The Author(s). Published by S. Karger AG, Basel.

Références

J Dermatolog Treat. 2020 Aug;31(5):496-510
pubmed: 31625775
Nature. 2017 Feb 2;542(7639):115-118
pubmed: 28117445
Telemed J E Health. 2016 Jan;22(1):45-50
pubmed: 26218353
J Invest Dermatol. 2018 Jul;138(7):1529-1538
pubmed: 29428356
JAMA Dermatol. 2019 Oct 01;155(10):1135-1141
pubmed: 31411641
J Invest Dermatol. 2021 Apr;141(4):916-920
pubmed: 32931808
Eur J Cancer. 2021 Oct;156:202-216
pubmed: 34509059
Comput Med Imaging Graph. 2008 Oct;32(7):566-79
pubmed: 18703311
Chin Med J (Engl). 2020 Sep 5;133(17):2020-2026
pubmed: 32810047
J Dermatolog Treat. 2022 Jun;33(4):2257-2262
pubmed: 34154489
Br J Dermatol. 2020 Jun;182(6):1388-1394
pubmed: 31449661
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Lancet Digit Health. 2022 Jan;4(1):e64-e74
pubmed: 34772649
JAMA Dermatol. 2022 Jan 01;158(1):90-96
pubmed: 34851366
Data Brief. 2020 Aug 25;32:106221
pubmed: 32939378
PLoS One. 2013 Nov 04;8(11):e76212
pubmed: 24223698
J Clin Aesthet Dermatol. 2009 Oct;2(10):34-6
pubmed: 20725572
JAMA Dermatol. 2020 Jan 1;156(1):29-37
pubmed: 31799995
J Dermatolog Treat. 2016;27(3):290-1
pubmed: 26418077
Med. 2021 Jan 15;2(1):6-10
pubmed: 35590133
JAMA Netw Open. 2019 Oct 2;2(10):e1913436
pubmed: 31617929
BMJ. 2020 Feb 10;368:m127
pubmed: 32041693
J Med Syst. 2019 Jul 13;43(8):283
pubmed: 31300897
Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:3905-3908
pubmed: 31946726
Nat Med. 2020 Aug;26(8):1229-1234
pubmed: 32572267
PLoS One. 2018 Mar 7;13(3):e0193321
pubmed: 29513718
JAMA Dermatol. 2018 Nov 1;154(11):1247-1248
pubmed: 30073260
Br J Dermatol. 2019 Feb;180(2):373-381
pubmed: 29953582
Lancet Oncol. 2019 Jul;20(7):938-947
pubmed: 31201137
Nat Med. 2020 Jun;26(6):900-908
pubmed: 32424212
JAMA Dermatol. 2017 Feb 01;153(2):207-213
pubmed: 27892996
Arch Intern Med. 2006 Sep 25;166(17):1907-14
pubmed: 17000949
JAMA Dermatol. 2021 Nov 01;157(11):1362-1369
pubmed: 34550305
J Dermatol. 2021 Mar;48(3):310-316
pubmed: 33211346
Chin Med J (Engl). 2020 Sep 5;133(17):2027-2036
pubmed: 32826613
J Am Acad Dermatol. 2022 Apr;86(4):950-951
pubmed: 33812954
Sci Data. 2021 Jan 28;8(1):34
pubmed: 33510154
Int J Dermatol. 2007 Aug;46(8):835-9
pubmed: 17651167
Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:5437-40
pubmed: 24110966
Sensors (Basel). 2019 Nov 14;19(22):
pubmed: 31739464
J Dermatol. 2021 Feb;48(2):232-236
pubmed: 33063398
BMC Med Inform Decis Mak. 2018 Jul 23;18(Suppl 2):59
pubmed: 30066649
Br J Dermatol. 2002 Sep;147(3):481-6
pubmed: 12207587
J Healthc Eng. 2020 Aug 1;2020:1713904
pubmed: 32832046
J Am Acad Dermatol. 2016 Nov;75(5):983-991
pubmed: 27476974
J Invest Dermatol. 2020 Sep;140(9):1753-1761
pubmed: 32243882
Biomolecules. 2020 Jul 29;10(8):
pubmed: 32751349
Sci Data. 2018 Aug 14;5:180161
pubmed: 30106392
J Am Acad Dermatol. 2017 Jun;76(6):1224-1225
pubmed: 28522052
Skin Res Technol. 2021 Jan;27(1):74-79
pubmed: 32772400
J Med Internet Res. 2021 Nov 24;23(11):e22934
pubmed: 34821566
PLoS Med. 2020 Nov 25;17(11):e1003381
pubmed: 33237903

Auteurs

Yuyang Liu (Y)

The University of Queensland, Faculty of Medicine, Brisbane, Queensland, Australia.

Clare A Primiero (CA)

The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.

Vishnutheertha Kulkarni (V)

The University of Queensland, Faculty of Medicine, Brisbane, Queensland, Australia, vishnutheertha96@gmail.com.

H Peter Soyer (HP)

The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.
Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Brigid Betz-Stablein (B)

The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH